Viral rebound common in lung transplant recipients treated with nirmatrelvir/ritonavir for COVID-19

Eli Lil­ly is ex­pect­ing sup­ply dis­rup­tions for its block­buster weight loss and di­a­betes prod­ucts to con­tin­ue through the end of this year, ex­ec­u­tives told in­vestors.

Con­tract de­vel­op­er and man­u­fac­tur­er Charles Riv­er Lab­o­ra­to­ries is hop­ing to re­duce re­liance on an­i­mal test­ing with a $500 mil­lion launch of its Al­ter­na­tive Meth­ods Ad­vance­ment